Tuberculosis Drug Discovery and Development
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2019) | Viewed by 7561
Special Issue Editors
Interests: medicinal chemistry; synthesis; drug delivery; neglected diseases
Interests: diffraction techniques; structure elucidation; conformation of bioactive compounds; antitubercular and anticancer agents; metal complexes, protein–protein interaction inhibitors; enzymatic inhibitors; multi-target drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce that submissions for the Molecules Special Issue “Tuberculosis in Drug Discovery and Development” are now open.
According to the World Health Organization, tuberculosis, caused by Mycobacterium tuberculosis, is an infectious disease that causes the highest number of deaths worldwide. Standard treatments with antibiotics are long and complex, and drug resistance is growing rapidly: even for recently approved bedaquiline, delamanid, and linezolid, resistance has already emerged. Thus, there is a great unmet medical need and, consequently, a great interest in the opportunities and challenges associated with tackling tuberculosis, in order to develop effective and, possibly, cheap antimycobacterial agents endowed with new mechanisms of action.
This issue will cover multiple aspects of the search for new molecules starting both from natural and synthetic compounds and addressing different or multiple targets (multitarget drugs) in Mycobacterium tuberculosis. Original research articles, as well as reviews, that are able to make substantial advances in this field are welcome.
Prof. Dr. Luca Costantino
Prof. Dr. Fiorella Meneghetti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Small molecules
- Peptides
- Peptidomimetics
- Mycobacterial target
- Drug design
- Computational tools
- Resistance mechanisms
- Crystallography
- Structure-property relationships
- Bioavailability
- Pharmacokinetics
